All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How do we select a patient with R/R DLBCL for CAR-T?

During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub spoke to Catherine Thieblemont, Hôpital Saint-Louis, Paris, FR. We asked, How do we select a patient with relapsed/refractory diffuse large B-cell lymphoma for CAR-T cell therapy?

How do we select a patient with R/R DLBCL for CAR-T?

Thieblemont summarizes the three main criteria in patient selection. The first, she explains, involves evaluation of disease progression and evolution. For the second she highlights that age is not a barrier, as shown in the ZUMA-1 trial. Finally she explains the importance of evaluating organ function and comorbidities.